Recombinant BD5 Human Protein [E. Coli.] (MAG-1314)

BD5 Human Protein

MAG-1314

His

Escherichia Coli.

At Room Temperature

BD5 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 51 amino acids and having a molecular mass of 5.8 kDa. The Beta Defensin-5 is purified by proprietary chromatographic techniques.

Beta-defensin 105, eta-defensin 5, BD-5, DEFB-5, Defensin, beta 105, DEFB105A, BD5, DEFB105, DEFB5, DEFB105B.

Defensins (alpha & beta) are cationic peptides with a wide spectrum of antimicrobial activity which include a significant arm of the innate immune system. There are 6 human beta-defensins, BD-1, BD-2, BD-3, BD-4, BD-5 and BD-6 which are expressed on some leukocytes and at epithelial surfaces. In addition to their direct antimicrobial activities, beta-defensins can act as chemoattractants towards immature dendritic cells and memory T cells. Beta-defensins contain a 6-cysteine motif which forms 3 intra-molecular disulfide bonds.

/

Sterile Filtered White lyophilized (freeze-dried) powder.

Lyophilized from a 0.2µm filtered concentrated solution in PBS, pH 7.4.

It is recommended to reconstitute the lyophilized Beta Defensin-5 in sterile 18M-cm H 2 O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

Lyophilized Beta Defensin-5 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution BD5 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Greater than 95.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.

GLDFSQPFPS GEFAVCESCK LGRGKCRKEC LENEKPDGNC RLNFLCCRQR I.

Mabioway's Co., Ltd products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Beta Defensin-5 Human Recombinant: Unleashing the Potential of an Emerging Antimicrobial Peptide Abstract: Beta Defensin-5 (hBD-5) human recombinant is an intriguing antimicrobial peptide with diverse properties and promising therapeutic applications. This research paper aims to provide a comprehensive analysis of hBD-5, including its characteristics, mode of action, and potential uses. Furthermore, innovative methodologies for the production and optimization of hBD-5 human recombinant are proposed, offering insights into its future implications in the field of infectious disease management. Introduction: The emergence of drug-resistant infections demands innovative solutions to combat pathogens. Antimicrobial peptides, such as hBD-5, have attracted attention due to their broad-spectrum activity. This paper explores the unique features of hBD-5 and presents novel approaches for its production and optimization. Characteristics and Mode of Action: hBD-5 is a cationic peptide composed of 41 amino acids and possesses a distinctive structure that contributes to its antimicrobial properties. The mechanism of action involves the disruption of microbial membranes and subsequent destruction of pathogens. Additionally, hBD-5 exhibits immunomodulatory effects by stimulating immune cells and modulating the inflammatory response. Production of hBD-5 Human Recombinant: Efficient production methodologies are crucial for the therapeutic application of hBD-5 human recombinant. Various expression systems, including bacterial, yeast, and mammalian cell-based platforms, have been investigated. Each system presents unique advantages and challenges, requiring careful selection to achieve high yields and protein quality. Optimization strategies, such as codon optimization, fusion protein tags, and growth conditions, have been implemented to enhance production efficiency. Purification techniques, such as chromatography and ultrafiltration, have been optimized to isolate high-quality hBD-5 recombinant. Potential Applications: hBD-5 human recombinant holds great promise for the treatment of drug-resistant pathogens. Its broad-spectrum antimicrobial activity against bacteria, viruses, and fungi positions it as a valuable therapeutic agent for infectious disease management. Moreover, hBD-5 exhibits potential in wound healing and tissue regeneration, as it promotes cell migration and angiogenesis. Exploring its potential as an adjuvant therapy in combination with existing antibiotics is an exciting area for future research. Conclusion: hBD-5 human recombinant represents an emerging antimicrobial peptide with diverse therapeutic potential. Optimizing production methodologies and elucidating its mechanisms of action will further enhance its clinical utility. With its broad-spectrum antimicrobial activity and potential implications in wound healing and adjuvant therapy, hBD-5 human recombinant holds promise as an innovative therapeutic tool.